Benjamin S. Braun

Hematology | Oncology
400 Parnassus Ave Fl 1
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.

TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology
Published: April 08, 2025

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.

Journal: Pediatric blood & cancer
Published: October 29, 2024

Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.

Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.

Journal: Nature communications
Published: May 29, 2024

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.

Journal: Research square
Published: February 05, 2024

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.

Journal: EJNMMI research
Published: January 16, 2024

Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.

Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.

Journal: Pediatric blood & cancer
Published: December 16, 2022

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.

Journal: Haematologica
Published: May 20, 2022

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.

Journal: Blood advances
Published: November 04, 2020

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.

Journal: Haematologica
Published: June 11, 2020

KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.

KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.

Journal: JCI insight
Published: May 27, 2020

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.

Journal: Blood advances
Published: August 27, 2019

Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.

Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.

Journal: Leukemia
Published: April 22, 2019
Showing 1-12 of 24

Last Updated: 09/26/2026